```html

Small Intestinal Bacterial Overgrowth (SIBO) – A Complete Medical Guide

Overview

Small Intestinal Bacterial Overgrowth (SIBO) is a condition in which unusually high numbers of bacteria colonize the small intestine, the part of the gastrointestinal (GI) tract that normally contains relatively few microbes. When these bacteria ferment the nutrients that pass through the small intestine, they produce gases and toxic by‑products that disturb digestion and nutrient absorption.

• Who it affects: Adults of any age, but it is most common in people aged 30–70 years.
• Prevalence: Estimates vary because SIBO is under‑diagnosed, but studies suggest it may affect 6–15 % of the general population and up to 40 % of patients with irritable bowel syndrome (IBS) (Mayo Clinic; NIH).
• Gender: Slightly more common in women, mirroring the higher prevalence of IBS.

Symptoms

SIBO can produce a broad spectrum of GI and systemic symptoms. The severity often depends on the type of bacteria (hydrogen‑producing, methane‑producing, or mixed) and the length of time the overgrowth has persisted.

Digestive symptoms

• Abdominal bloating – a feeling of fullness or swelling, often worse after meals.
• Excessive gas (flatulence) – due to bacterial fermentation of carbohydrates.
• Abdominal pain or cramping – usually intermittent and related to gas buildup.
• Diarrhea – common with hydrogen‑dominant SIBO; stools may be loose, watery, and frequent.
• Constipation – more typical of methane‑dominant SIBO; stools may be hard and difficult to pass.
• Indigestion (dyspepsia) – heartburn, nausea, or a feeling of early satiety.
• Steatorrhea (fatty stools) – occurs when bacteria deconjugate bile acids, impairing fat absorption.

Systemic symptoms

• Unexplained weight loss – malabsorption of calories, fats, and proteins.
• Fatigue or brain fog – due to nutrient deficiencies and chronic inflammation.
• Muscle weakness or joint pain – linked to vitamin B12, iron, or magnesium deficiency.
• Skin changes – such as rash or eczema, occasionally reported in severe cases.

Causes and Risk Factors

SIBO is usually not caused by a single factor; rather, it results from conditions that disrupt the normal protective mechanisms of the small intestine.

Mechanisms that normally prevent bacterial overgrowth

• Motility (the migrating motor complex) – “house‑keeping” waves that sweep bacteria downstream.
• Acidic gastric secretions – kill many ingested microbes.
• Intact ileocecal valve – prevents colonic bacteria from refluxing upward.
• Immune surveillance – secretory IgA and gut‑associated lymphoid tissue keep bacterial numbers low.

Common precipitating factors

• Motility disorders – diabetes‑related neuropathy, scleroderma, hypothyroidism, or chronic opioid use.
• Structural abnormalities – surgical blind loops, strictures, adhesions, or diverticula.
• Low stomach acid (hypochlorhydria) – from long‑term proton pump inhibitor (PPI) use or atrophic gastritis.
• Immune deficiencies – HIV, common variable immunodeficiency, or use of immunosuppressants.
• Underlying GI diseases – Crohn’s disease, celiac disease, chronic pancreatitis, or irritable bowel syndrome.
• Medications – PPIs, antibiotics that disturb normal flora, and certain anticholinergics.
• Age – intestinal motility naturally slows with age, increasing risk.

Diagnosis

Because symptoms overlap with IBS, chronic fatigue syndrome, and many other disorders, a systematic approach is essential.

1. Clinical evaluation

• Detailed history of GI symptoms, medication use, surgeries, and risk factors.
• Physical exam focusing on abdominal tenderness, bloating, and signs of malnutrition.

2. Breath tests

The most widely used non‑invasive tools are hydrogen and methane breath tests.

• Glucose Breath Test (GBT) – 75 g glucose is ingested; elevated hydrogen or methane at 20‑90 minutes suggests SIBO.
• Lactulose Breath Test (LBT) – 10 g lactulose triggers gas production; a rise in hydrogen or methane within 90 minutes is considered positive.
• Interpretation should follow criteria set by the North American Consensus (2021) – a rise of ≥20 ppm hydrogen or ≥10 ppm methane above baseline.

3. Direct sampling (less common)

• Aspirate and culture – Endoscopic collection of fluid from the jejunum; >10⁵ colony‑forming units/mL is diagnostic but invasive and rarely performed.

4. Ancillary tests

• Complete blood count, vitamin B12, ferritin, folate, and vitamin D to assess malabsorption.
• Fecal fat test if steatorrhea is present.
• Imaging (CT, MRI, or small‑bowel follow‑through) when structural causes are suspected.

Treatment Options

Therapy aims to eradicate excess bacteria, restore normal motility, and correct nutrient deficiencies.

1. Antibiotics

Antibiotic	Typical Regimen	Comments
Rifaximin (Xifaxan)	550 mg PO three times daily for 14 days	First‑line for hydrogen‑dominant SIBO; minimal systemic absorption.
Neomycin	500 mg PO twice daily for 14 days (often combined with rifaximin for methane‑dominant SIBO)	Effective against methane‑producing archaea.
Metronidazole	500 mg PO three times daily for 7‑10 days	Alternative; may cause GI upset.
Azithromycin	500 mg PO daily for 3 days	Useful in patients who cannot tolerate rifaximin.

Recurrence rates range from 30 % to 70 %; repeat courses or rotating antibiotics may be required (Cleveland Clinic).

2. Prokinetic agents

• Prucalopride or erythromycin low‑dose to stimulate migrating motor complex.
• Used after antibiotics to prevent relapse, especially in motility‑related SIBO.

3. Dietary management

• Low FODMAP diet – reduces fermentable carbohydrates that feed bacteria.
• Specific Carbohydrate Diet (SCD) – limits complex sugars.
• Both should be supervised by a registered dietitian to avoid micronutrient deficiencies.

4. Nutrient repletion

• Vitamin B12 (intramuscular or high‑dose oral), iron, folate, and fat‑soluble vitamins (A, D, E, K) as indicated.
• Consider magnesium, zinc, and calcium supplementation if labs are low.

5. Probiotics & herbal antimicrobials

Evidence is mixed; some patients benefit from Oregano oil, berberine, or a multi‑strain probiotic after antibiotics, but these should not replace evidence‑based therapy (NIH).

Living with Small Intestinal Bacterial Overgrowth (SIBO)

Long‑term management focuses on symptom control, preventing recurrence, and maintaining nutritional status.

Daily habits

• Eat regular, moderate‑sized meals – avoid long fasting periods that can disrupt motility.
• Chew food thoroughly – aids digestion and reduces substrate for bacterial fermentation.
• Stay hydrated – 1.5–2 L of water daily unless contraindicated.
• Physical activity – Light walking after meals stimulates intestinal motility.
• Limit alcohol and smoking – Both impair gut motility and mucosal immunity.

Nutrition tips

• Follow a personalized low‑FODMAP or SCD plan for 4–6 weeks, then slowly re‑introduce foods to identify triggers.
• Incorporate lean protein (fish, poultry, tofu) and low‑carb vegetables (spinach, zucchini, carrots).
• Use digestive enzymes (e.g., lactase) if lactose intolerance co‑exists.
• Track symptoms in a diary – note foods, timing, and severity to share with your clinician.

Follow‑up care

• Repeat breath test 1–3 months after completing antibiotics to confirm eradication.
• Quarterly labs for B12, iron, and vitamin D for the first year.
• Consider a “maintenance” low‑dose antibiotic or cyclic probiotic regimen if relapses are frequent.

Prevention

While some risk factors (e.g., prior surgery) cannot be changed, several strategies lower the chance of developing SIBO.

• Limit long‑term use of PPIs – use the lowest effective dose, and discontinue when no longer needed.
• Manage chronic diseases – keep diabetes, hypothyroidism, and scleroderma under good control.
• Promote healthy gut motility – regular meals, adequate fiber (if tolerated), and gentle exercise.
• Avoid unnecessary antibiotics – they disrupt the balance of gut flora.
• Screen high‑risk patients (e.g., post‑surgical blind loops) with periodic breath testing.

Complications

If left untreated, SIBO can lead to serious health problems.

• Malabsorption and nutrient deficiencies – especially vitamin B12, iron, calcium, and fat‑soluble vitamins, which can cause anemia, osteoporosis, and neuropathy.
• Weight loss or failure to thrive – due to chronic caloric loss.
• Intestinal inflammation – chronic bacterial metabolites may provoke low‑grade inflammation, increasing the risk of IBS and, in rare cases, intestinal ulceration.
• Small‑bowel bacterial translocation – can predispose to systemic infections, especially in immunocompromised patients.
• Psychological impact – persistent bloating, pain, and dietary restrictions often lead to anxiety or depression.

When to Seek Emergency Care

References

• Mayo Clinic. “Small intestinal bacterial overgrowth (SIBO).” mayoclinic.org. Accessed June 2026.
• National Institutes of Health. “SIBO – Clinical Guidelines.” NIH Library of Medicine, 2022.
• Cleveland Clinic. “Small Intestinal Bacterial Overgrowth (SIBO) Treatment.” clevelandclinic.org.
• World Health Organization. “Guidelines for the Diagnosis of Gastrointestinal Disorders.” WHO, 2021.
• R. Ghoshal, et al. “The North American Consensus on Breath Testing for SIBO.” *American Journal of Gastroenterology*, 2021; 116(5): 833‑844.
• J. Pimentel, et al. “Rifaximin Therapy for SIBO: A Randomized Controlled Trial.” *Gastroenterology*, 2020; 158(2): 400‑410.

```